In previous studies we identified a pneumococcal surface protein (PspA) which acts as a virulence factor for pneumococci and can elicit antibodies that are able to protect mice from fatal pneumococcal infection. The presence of PspA on pneumococci slows their clearance from the blood. While it seems likely that PspA interferes with opsonophagocytosis, the mechanism of its action is not known. The N-terminal half (49%) of PspA from strain Rx1 is a highly charged alpha-helical sequence with a strong coiled-coil motif that is followed by a proline-rich central region, and a repeat region which serves to anchor PspA to the bacterial membrane. PspA lacks a sequence consistent with a transmembrane anchor and the LPXTGE sequence implicated in surface attachment of most previously described gram positive surface proteins. All protective monoclonal antibodies (MAb) to PspA react with its N-terminal half and immunization with this portion of the molecule can elicit protection against fatal pneumococcal infection. The N-terminal half of PspA exhibits a high degree of serologic variability. In spite of this variability, the N-terminal region of each PspA contains epitopes cross-reactive with those of many other PspA molecules. Immune responses to one PspA have been shown to protect mice against fatal infection with strains bearing cross-reactive but serologically distinct PspA molecules. Recent evidence indicates that most strains have two sequences which strongly hybridize with cloned pspA. On a few strains two different PspA molecules have been demonstrated. We propose to identify the protection eliciting epitopes of PspA, determine the structural basis for the antigenic variability in PspA, investigate the mechanism of action of PspA, and learn the extent to which immunity to PspA might be able to protect against diverse strains of pneumococci. The data obtained will also allow us to test several hypotheses, including: 1) that the variability of PspA is the result of evolution to avoid protective antibodies, and 2) that PspA acts an anchor to hold the capsular polysaccharide to the pneumococcal surface, and 3) that most strains pneumococci may have two different PspA molecules.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI021548-13
Application #
2003320
Study Section
Bacteriology and Mycology Subcommittee 2 (BM)
Project Start
1984-08-01
Project End
1997-12-31
Budget Start
1997-01-01
Budget End
1997-12-31
Support Year
13
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Microbiology/Immun/Virology
Type
Schools of Dentistry
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Walker, Melissa M; Novak, Lea; Widener, Rebecca et al. (2016) PcpA Promotes Higher Levels of Infection and Modulates Recruitment of Myeloid-Derived Suppressor Cells during Pneumococcal Pneumonia. J Immunol 196:2239-48
Hotomi, Muneki; Yuasa, Jun; Briles, David E et al. (2016) Pneumolysin plays a key role at the initial step of establishing pneumococcal nasal colonization. Folia Microbiol (Praha) 61:375-83
Dennis, Evida A; Coats, Mamie T; Griffin, Sarah E et al. (2015) The Effects of CFTR and Mucoid Phenotype on Susceptibility and Innate Immune Responses in a Mouse Model of Pneumococcal Lung Disease. PLoS One 10:e0140335
Kim, Ji-Yun; Paton, James C; Briles, David E et al. (2015) Streptococcus pneumoniae induces pyroptosis through the regulation of autophagy in murine microglia. Oncotarget 6:44161-78
Schachern, Patricia A; Tsuprun, Vladimir; Ferrieri, Patricia et al. (2014) Pneumococcal PspA and PspC proteins: potential vaccine candidates for experimental otitis media. Int J Pediatr Otorhinolaryngol 78:1517-21
Zhao, H; Jung, J A; Briles, D E et al. (2013) Asthma and antibodies to pneumococcal virulence proteins. Infection 41:927-34
Genschmer, Kristopher R; Accavitti-Loper, Mary Ann; Briles, David E (2013) A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA). Vaccine 32:39-47
Ren, Bing; Li, Jie; Genschmer, Kristopher et al. (2012) The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci in vitro. Clin Vaccine Immunol 19:1574-82
Park, In Ho; Kim, Kyung-Hyo; Andrade, Ana Lucia et al. (2012) Nontypeable pneumococci can be divided into multiple cps types, including one type expressing the novel gene pspK. MBio 3:
Singh, Rajesh; Singh, Shailesh; Briles, David E et al. (2012) CCL5-independent helper T lymphocyte responses to immuno-dominant pneumococcal surface protein A epitopes. Vaccine 30:1181-90

Showing the most recent 10 out of 107 publications